A randomized placebo-controlled trial of arbaclofen vs. placebo in the treatment of children and adolescents with ASD.
Medication Clinical Trials
Summary
We are currently investigating a study drug called arboclofen to improve social functioning in children and teens with Autism.
Call to action
Have you been diagnosed with an autism spectrum disorder? Do you have social difficulties and/or repetitive behaviours? You may be eligible to participate in a clinical trial of a medication called arbaclofen!
Who can participate
Children and teens between 5-17 years of age with a diagnosis of an autism spectrum disorder (ASD, autism, PDD-NOS, or Asperger's syndrome).
What's involved
The trial will last a total of 18 weeks (4.5 months) and involves taking either arbaclofen or a placebo, as a meltaway tablet, 1-3 times per day for 18 weeks. You and your child will first be asked to come in for a screening session; through talking with you and completing some assessments, we will determine if your child meets eligibility criteria.
Visits will occur at Holland Bloorview and will take place every 2-4 weeks while you child is taking the drug or placebo. This study also has an optional continuation part, which means that all participants will be able to take arbaclofen at the end of the 18 weeks. The same tests and procedures will be followed that were followed during the main study.
Participants will receive a small token of appreciation in the form of a $20.00 gift card to thank them for their time.
Deadline
The study will be in January 2018 and recruit for up to 18 months.
Interested in participating?
If you are interested in participating in this study or have additional questions, please contact Leanne Ristic at 416-425-6220 ex 3469 or npeleg@hollandbloorview.ca with your interest, and they will get back to your shortly. Contacting us does not obligate you or your child to participate in the study.
